Skip to main content
. 2021 Aug 10;5:75. doi: 10.1038/s41698-021-00215-x

Fig. 1. Representative diagram of how acquired resistance to rux was modeled using ATF7IP-JAK2 Ba/F3 cells.

Fig. 1

a Three biological replicates of ATF7IP-JAK2 Ba/F3 cells were treated with a rux dose escalation for 3 months until resistance to the clinically relevant dose of 1 µM rux was achieved. Each of the three rux-resistant (RuxR) ATF7IP-JAK2 Ba/F3 cells acquired independent resistance to rux. Concurrently, ATF7IP-JAK2 Ba/F3 cells were cultured without treatment (Naïve) or treated with vehicle control (0.1% DMSO) to generate control cell lines. b Representative diagram of the ATF7IP-JAK2 fusion gene indicating localization of acquired point mutations within the JAK2 kinase domain. Annotations were made using the NCBI reference sequences for JAK2 variant 1 (NM_004972.4) and ATF7IP (NM_181352.2).